Quarterly ResultAug 5, 2026, 07:37 AM
Rapport Therapeutics Q2 Net Loss $56.6M; R&D Expenses Up 126%
AI Summary
Rapport Therapeutics reported a Q2 2026 net loss of $56.6 million, widening from $26.7 million in Q2 2025. For the six months, net loss was $76.5 million, driven by a 126% increase in research and development expenses to $51.4 million in Q2 2026. The company recognized $20 million in collaboration revenue for the six-month period and ended the quarter with $436.1 million in cash, cash equivalents, and short-term investments, expecting to fund operations for at least 12 months.
Key Highlights
- Q2 2026 net loss was $(56.6) million, compared to $(26.7) million in Q2 2025.
- Six-month 2026 net loss was $(76.5) million, up from $(50.8) million in 2025.
- Q2 2026 R&D expenses increased 126% to $51.4 million from $22.7 million.
- Six-month 2026 collaboration revenue was $20.0 million, up from $0 in 2025.
- Cash, cash equivalents, and short-term investments totaled $436.1 million.
- Accumulated deficit reached $(311.7) million as of June 30, 2026.
- Net cash used in operating activities was $(54.5) million for six months.
Price Impact
More from RAPP